An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
RenovoRx to Participate in Upcoming H.C Wainwright Global Investment Conference in May 2022
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
RenovoRx, a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami Beach, Florida. CEO Shaun Bagai is set to present on May 24 at 7:00 a.m. ET. The company specializes in localized treatments for cancer using its proprietary RenovoTAMP therapy platform. RenovoRx's lead product, RenovoGem, aims to treat locally advanced pancreatic cancer and is currently in Phase 3 trials. The event will also offer one-on-one meetings with investors.
Positive
None.
Negative
None.
LOS ALTOS, Calif.--(BUSINESS WIRE)--
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced management’s participation in the H.C. Wainwright Global Investment Conference on May 23-26, 2022 in Miami Beach, Florida.
Shaun Bagai, RenovoRx’s CEO, will provide a Company update and will participate in one-on-one meetings with the investment community. Attendees include public companies, and institutional and private investors. To schedule a meeting, please reach out to your H.C. Wainwright representative or send an email to KCSA Strategic Communications at RenovoRx@KCSA.com.
A recording of this presentation will be posted to the RenovoRx Website Events page when it becomes available.
About RenovoRx, Inc.
RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP™) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. RenovoRx’s lead product candidate, RenovoGem™, is a combination of gemcitabine and our patented delivery system, RenovoCath®, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). RenovoGem is currently being studied in the Phase 3 TIGeR-PaC trial for the treatment of LAPC.
RenovoRx’s patent portfolio includes seven U.S. patents for its technology. RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer.
RenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards – Life Sciences Edition 2020 for its RenovoTAMP technology.
